Table 1 Patient characteristics.
Total | MAC | RIC | |
|---|---|---|---|
n = 116 | n = 36 (31%) | n = 80 (69%) | |
Age, years median (range) | 59.1 (24.6–73.9) | 54.5 (26.1–64.5) | 63.7 (24.6–73.9) |
Sex, male | 71 (61.2%) | 22 (61.1%) | 49 (61.3%) |
Disease | |||
Myeloid neoplasm | 76 (65.5%) | 22 (61.1%) | 54 (67.5%) |
AML | 49 (42%) | 11 (30.6%) | 38 (47.5%) |
MDS | 16 (13.8%) | 6 (16.7%) | 10 (12.5%) |
MPN | 11 (9.5%) | 5 (13.9%) | 6 (7.5%) |
Lymphoid neoplasm | 40 (34.5%) | 14 (38.9%) | 26 (32.5%) |
ALL | 8 (6.9%) | 3 (8.3%) | 5 (6.3%) |
High grade NHL | 13 (11.2%) | 4 (11.1%) | 9 (11.2%) |
Low grade NHL | 10 (8.6%) | 3 (8.3%) | 7 (8.8%) |
HL | 2 (1.7%) | 1 (2.8%) | 1 (1.3%) |
T NHL | 7 (6.0%) | 3 (8.3%) | 4 (5%) |
Disease risk index | |||
Low | 16 (13.8%) | 5 (13.9%) | 11 (13.8%) |
Int | 84 (72.4%) | 29 (80.6%) | 55 (68.8%) |
High | 14 (12.1%) | 2 (5.6%) | 12 (15.0%) |
Very high | 1 (0.9%) | 0 (0%) | 1 (1.3%) |
Donors | |||
HLA-identical sibling | 33 (28.4%) | 7 (19.4%) | 26 (32.5%) |
10/10 MUD | 70 (60.3%) | 20 (55.6%) | 50 (62.5%) |
9/10 MUD | 13 (11.2%) | 9 (25%) | 4 (5%) |
Conditionning | |||
CloB2A1 | 29 (25.0%) | 29 (36.2%) | |
CloB2A2 | 12 (10.3%) | 12 (15.0%) | |
FB2A2 | 39 (33.6%) | 39 (48.8%) | |
FB3A2 | 27 (23.3%) | 27 (75.0%) | |
FB4A2 | 9 (7.8%) | 9 (25.0%) | |
Median ALC/ATG × 109/L (range) | 0.070 (0–2.3) | 0.1 (0.01–1.2) | 0.055 (0–2.3) |
